ÂÜÀòÂÒÂ×

Kapil Dhingra is an experienced professional in the biotechnology and pharmaceutical sectors, currently serving as a Member of the Board of Directors at CARGO Therapeutics, Servier, Mariana Oncology, Black Diamond Therapeutics, and REPLIMUNE LIMITED, as well as Chairman of the Board of Directors at Lava Therapeutics B.V. Since 2008, Kapil Dhingra has been the Managing Member of KAPital Consulting LLC. Previous roles include being an Associate Editor for Annals of Oncology and a Board Member at Autolus Ltd. until December 2023 and at Five Prime Therapeutics, which was acquired by Amgen for $1.9 billion. Educational qualifications include earning a Doctor of Medicine (M.D.) degree from the All India Institute of Medical Sciences from 1976 to 1983.